Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry

• Published in: Therapeutic drug monitoring Vol. 46; no. 5; p. 634
• Main Authors: Guo, Yu-Jiao, Du, Tian-Tian, Yang, Yan-Ling, Zhao, Yang, Chen, Xiang-Long, Ma, Hong, Sun, Lu-Ning, Wang, Yong-Qing
• Format: Journal Article
• Language: English
• Published: United States 01.10.2024
• Subjects: Adenine - analogs & derivatives; Adenine - blood; Adenine - therapeutic use; Chromatography, Liquid - methods; Humans; Liquid Chromatography-Mass Spectrometry; Piperidines - blood; Piperidines - therapeutic use; Protein Kinase Inhibitors - blood; Protein Kinase Inhibitors - therapeutic use; Pyrazines - blood; Pyrazines - therapeutic use; Pyrazoles - blood; Pyrazoles - therapeutic use; Pyrimidines - blood; Pyrimidines - therapeutic use; Reproducibility of Results; Tandem Mass Spectrometry - methods

Ibrutinib and zanubrutinib are Bruton tyrosine kinase inhibitors used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Dihydroxydiol ibrutinib (DHI) is an active metabolite of the drug. A liquid chromatography-tandem mass spectrometry method was developed...